**Technology**

**Results** The failure modes that show higher benefits in risk mitigation are the wrong drug and wrong dosage with a PRI decrease of 80% (from 50 to 10). Indeed the redundant controls (vision system, scale, photocells) on the loaded vials guarantee the compounding of the right drug. In addition, the drug is dosed with a calibrated syringe pump and independently verified with the scale. The other failure modes reported a risk reduction of 50% and on the whole the total PRI passes from 186 in case of the manual activity to 63 for the robotic one.

**Conclusions** The FMECA analysis shows an overall reduction of the PRIs of over 66% with the robotic compounding with respect to the manual production. Automation not only decreases the occurrence of dangerous events thanks to the complete control of every single step of the compounding process, but also develops an error detection system through independent verification processes.

No conflict of interest.

**SHORTAGE OF STERILE CALCIUM GLUCONATE STOCK SOLUTION FOR PARENTERAL NUTRITION: WHAT IS THE ALTERNATIVE AND HOW MUCH DOES IT COST?**

1. V. Signor, 1’ S. Serraro, 1’ P. Jonret, 1’ P. Vaconsin, 1’ F. Briot, 1’ T. Storne, 1’ M. Perrinet, 1’ APHP (Hôpital Robert Debré), Pharmacy, Paris, France; 2’ Univ Paris Descartes, Clinical Pharmacy, Paris, France

**Background** The Total Parenteral Nutrition (TPN) production facility of our children’s hospital produces around 20,000 units per year with 2 Baxa EM2400 compounders. In June 2012, a shortage of the calcium source (10% sterile solution of calcium gluconate in 500 mL bottles) occurred. To overcome this problem, we first tried to import an alternative source but the administrative delay was too long. The only sources available within a month were 10 mL plastic or glass ampoules. The estimated consumption was around 300 ampoules per production day. To maintain efficiency and safety in the TPN facility, it was decided to produce calcium gluconate bags from 10 mL ampoules by sterilising filtration to maintain the safety of preparation.

**Purpose** To evaluate the additional cost incurred by setting up this production and the increased time required.

**Materials and Methods** The pharmacy prepared calcium gluconate bags (250 mL) from plastic ampoules after filtration (0.22 µm filters (Sterivex Millipore), using a Repeater Pump (Baxter), in a laminar air flow cabinet. The cost of setting up a new procedure and of the compounding was evaluated in different categories (materials, checking, staff).

**Results** 228 bags were produced during the 20 days on which we could not obtain the 500 mL bottles (19 batches of 12 bags).

The cost of one 250 mL compound bag was €44.23 (materials: 25.5, checking: €5.75, staff: €13). In addition, developing the compounding was evaluated in different categories (materials, checking, staff).

**Conclusions** Despite a major additional cost, compounding calcium gluconate bags has ensured the continued production of TPN. From a risk assessment point of view, identification of several suppliers and increasing our stocks of the raw materials would make out-of-stock situations easier to manage in future.

No conflict of interest.

**STABILITY OF FROZEN CEFTAZIDIME SOLUTION IN POLYPROPYLENE SYRINGES FOR INTRAVITREAL INJECTION**

1. J. Vigneron, A. Daul, N. Sobalak, H. Zenier, I. May, B. Demoré. Centre Hospitalier Universitaire de Brabois, Pharmacy, Vandoeuvre, France

**Background** Ceftazidime is used for the treatment of endophthalmitis by intravitreal injection. For this emergency treatment, the syringes must be available immediately in the pharmacy. The stability at 2–8°C is limited and does not allow batch production.

**Purpose** To study the stability of ready-to-use ceftazidime solution at 20 mg/mL in 0.9% sodium chloride in polypropylene syringes after storage at −20°C, to allow preparation in advance.


The analytical conditions were: Column C18 5 µm x 4.6 mm. Mobile phase (ammonium acetate buffer 0.1 M pH 7.5/acetonitrile 90/10), flow rate: 1 mL/min, wavelength: 256 nm.

The HPLC method was validated according to ICH guidelines (linearity, repeatability, stability-indicating capability).

Syringes were stored at −20°C and 4°C for comparison with literature data.

**Results** Stability was defined according to ICH guideline Q1A: above 95% of the initial concentration of ceftazidime and concentration of degradation products less than 2%. After storage at 4°C, the ceftazidime concentration fell under 90% after 3 weeks and there was 65% of the initial concentration after 90 days.

The ceftazidime solution at 20 mg/mL was stable for 3 months at −20°C with more than 96% of the initial concentration and degradation products under 0.8%.

**Conclusions** Ceftazidime 20 mg/mL in 0.9% sodium chloride was stable for 3 months at −20°C. This allows batch preparation in advance and the immediate availability of the syringes to treat patients.

No conflict of interest.

**SIX SIGMA IN HEALTHCARE: AN APPLICATION IN THE MONITORING OF ALBUMIN**

1. F. Cirro, 1’ P. Marrone, 1’ R. Citalla, 1’ ARNAS Civico Hospital, Pharmacy Operative Unity, Palermo, Italy; 2’ University of Palermo, Engineering department, Palermo, Italy

**Background** The high off-label use of albumin persuaded the pharmacy to introduce a request form that uses the international guidelines to assess whether the use of albumin is appropriate. This has resulted in a clear reduction in the costs.

**Purpose** To monitor the wards using six sigma methodology (a statistical concept that measures a process in terms of defects); to ensure that all procedures have been followed correctly.

**Materials and Methods** 696 forms for albumin prescriptions coming from 26 wards (August to December 2011) were analysed using Minitab software, which cheques the frequency of the best correct requests (type 1), partially correct requests (type 2) and incorrect requests (type 3). For each ward the β coefficient was used to connect the relationship between the ward and their requests. The wards were grouped into 4 ranges on confidence intervals for the odds ratio (OR) of a width equal to 0.3 called A,B,C,D and then a final logistic regression analysis was made.

**Results** The analysis showed that group A was the most efficient in terms of probability of obtaining better results, followed by groups D (OR 0.36), C (OR 0.19) and B (OR 0.09). The total number of requests received was: 43% type 1 (299/696); 26% type 2 (181/696); 31% type 3 (216/696). Group B showed the worst result with 51% type 3 requests (58% of the total requests for type 3). Using six sigma we have achieved a cost saving of about €15,000.

**Conclusions** The results encourage us to apply this methodology to other fields.

No conflict of interest.

**References**

1. F. Cirro, 1’ P. Marrone, 1’ R. Citalla, 1’ ARNAS Civico Hospital, Pharmacy Operative Unity, Palermo, Italy; 2’ University of Palermo, Engineering department, Palermo, Italy

2. J. Vigneron, A. Daul, N. Sobalak, H. Zenier, I. May, B. Demoré. Centre Hospitalier Universitaire de Brabois, Pharmacy, Vandoeuvre, France

TCH-039 Six Sigma in Healthcare: An Application in the Monitoring of Albumin

F Cimo, P Marrone and R Citati

*Eur J Hosp Pharm* 2013 20: A82
doi: 10.1136/ejhpharm-2013-000276.230

Updated information and services can be found at:
http://ejhp.bmj.com/content/20/Suppl_1/A82.2

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Competing interests (ethics) (1710)
- IT (125)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/